Open Access

KIF9‑AS1 promotes nasopharyngeal carcinoma progression by suppressing miR‑16

  • Authors:
    • Huizeng You
    • Shuyong Wang
    • Sa Yu
  • View Affiliations

  • Published online on: September 15, 2020     https://doi.org/10.3892/ol.2020.12104
  • Article Number: 241
  • Copyright: © You et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Long non‑coding RNAs (lncRNAs) have been reported to serve a crucial role in the progression of nasopharyngeal carcinoma (NPC); however, the underlying molecular mechanisms of lncRNA KIF9‑AS1 in the tumorigenesis of NPC remains poorly understood. Reverse transcription‑quantitative PCR was used to analyze the expression levels of KIF9‑AS1 and microRNA (miR)‑16, and Cell Counting Kit‑8, wound healing and Transwell assays were used to determine the cell viability, invasion and migration, respectively, of NPC cells. In addition, a dual‑luciferase reporter assay was used to analyze the direct interaction between KIF9‑AS1 and miR‑16. NPC stage was classified according to the seventh edition of the AJCC staging system. The results revealed that KIF9‑AS1 expression levels were upregulated in NPC tissues and cell lines. In addition, miR‑16 was demonstrated to directly interact with KIF9‑AS1 and inhibit KIF9‑AS1 expression levels, whereas the miR‑16 inhibitor rescued the effects of the KIF9‑AS1‑knockdown in NPC cells. Furthermore, the expression levels of KIF9‑AS1 were upregulated, while those of miR‑16 were downregulated in NPC tissues. Notably, the expression levels of KIF9‑AS1 were observed to be significantly more upregulated in advanced tumors (III‑IV vs. I‑II) and patients with high KIF9‑AS1 expression levels exhibited a worse prognosis. In conclusion, the findings of the present study suggested that KIF9‑AS1 may promote the progression of NPC by targeting miR‑16, thus KIF9‑AS1 may be a novel molecular target for NPC therapy.

Related Articles

Journal Cover

November-2020
Volume 20 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
You H, Wang S and Yu S: KIF9‑AS1 promotes nasopharyngeal carcinoma progression by suppressing miR‑16. Oncol Lett 20: 241, 2020
APA
You, H., Wang, S., & Yu, S. (2020). KIF9‑AS1 promotes nasopharyngeal carcinoma progression by suppressing miR‑16. Oncology Letters, 20, 241. https://doi.org/10.3892/ol.2020.12104
MLA
You, H., Wang, S., Yu, S."KIF9‑AS1 promotes nasopharyngeal carcinoma progression by suppressing miR‑16". Oncology Letters 20.5 (2020): 241.
Chicago
You, H., Wang, S., Yu, S."KIF9‑AS1 promotes nasopharyngeal carcinoma progression by suppressing miR‑16". Oncology Letters 20, no. 5 (2020): 241. https://doi.org/10.3892/ol.2020.12104